Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals has published a shareholder update letter highlighting recent activities at the ASCP meeting. The company has reached a 9-month stability point with its ketamine formulation (NRX-100) and initiated 3 manufacturing lots. Nonclinical safety data for NRX-100 has been submitted to the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:34 pm

Ascendiant Capital has maintained its Buy rating on NRX Pharmaceuticals (NASDAQ:NRXP) but has lowered the price target from $50 to $43.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 3:58 pm

NRx Pharmaceuticals presented its Phase 2b/3 trial results for NRX-101 at the ASCP Annual Meeting. The trial showed that NRX-101 significantly reduces suicidality and symptoms of akathisia in bipolar depression compared to the standard treatment, lurasidone.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 12:47 pm

The article highlights significant intraday movements in health care stocks on Thursday. Notable gainers include Lucy Scientific Discovery (LSDI), SINTX Techs (SINT), Nanoviricides (NNVC), Scorpius Holdings (SCPX), Onconetix (ONCO), and NRX Pharmaceuticals (NRXP). Key losers are Eyenovia (EYEN), 180 Life Sciences (ATNF), Omeros (OMER), Elicio Therapeutics (ELTX), Biotricity (BTCY), and T2 Biosystems (TTOO). Several of these movements are linked to recent earnings reports.

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 4:31 pm

NRX Pharmaceuticals (NRXP) reported a Q1 EPS loss of $(0.74), missing the consensus estimate of $(0.37) by 100%. This represents a 53.75% improvement over the $(1.60) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:37 pm

Health care stocks experienced significant movements in Monday's intraday session, with NRX Pharmaceuticals, TC BioPharm, Outset Medical, Nanoviricides, Chemomab Therapeutics, and Titan Pharma among the gainers. Conversely, Lyra Therapeutics, GlycoMimetics, EyePoint Pharmaceuticals, Acutus Medical, Integra Lifesciences, and Helius Medical Technologies were notable losers. The movements were attributed to various factors, including earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 4:31 pm

NRx Pharmaceuticals shares surged following the announcement of a significant safety advantage of NRX-101 over the standard care in a clinical trial for suicidal bipolar depression, with plans to seek accelerated approval.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 2:18 pm

NRx Pharmaceuticals announced the final results of its clinical trial, indicating that its drug NRX-101 has shown to reduce akathisia while maintaining comparable antidepressant efficacy. The company believes these results may constitute a basis for seeking accelerated FDA approval for NRX-101.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm

In Tuesday's after-market session, several healthcare stocks showed significant movement. Predictive Oncology led the gainers with a 36.4% increase, while Concord Medical Services experienced the largest drop, declining by 23.3%. Notably, TransMedics Group and CVRx reported their Q1 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 8:31 pm

H&E Equipment Services, Inc. (HEES) shares fell by 18.2% following mixed Q1 results, missing EPS estimates but beating sales expectations. Other stocks experienced significant movements, with notable gainers including Akili, Inc. (AKLI) and losers like Lichen China Limited (LICN). Various companies reported financial results, strategic partnerships, and other business updates affecting their stock prices.

Portfolio Pulse from Avi Kapoor

April 30, 2024 | 5:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.